Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2009

01-05-2009 | Original Article

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

Authors: E. V. McCloskey, H. Johansson, A. Oden, S. Vasireddy, K. Kayan, K. Pande, T. Jalava, J. A. Kanis

Published in: Osteoporosis International | Issue 5/2009

Login to get access

Abstract

Summary

Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors. This study demonstrates that the estimation of an individual’s 10-year probability of fracture by the FRAX® algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy.

Introduction

Treatments for osteoporosis are targeted largely to patients with low bone density (BMD) or a prior fragility fracture. Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors, but it is important to determine whether the risk so identified can be reduced by intervention. We determined the effect of a bisphosphonate on fracture rates when risk was calculated using a new risk algorithm (FRAX®).

Methods

Women aged 75 years or more were recruited to a randomised, double-blind controlled trial of 800 mg oral clodronate (Bonefos®) daily over 3 years. Baseline clinical risk factors were entered in the FRAX® model to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD. The interaction between fracture probability and treatment efficacy was examined by Poisson regression.

Results

In 3,974 women, the interaction between fracture probability and treatment efficacy was significant when probability was assessed without BMD (p = 0.043), but not when BMD was included (p = 0.10). Efficacy was more evident in those deemed at highest risk. For example women lying at the 75th percentile of fracture probability in the absence of BMD (10-year probability 24%) treatment reduced fracture risk by 27% (HR 0.73, 95%CI 0.58–0.92). In those with a fracture probability of 30% (90th percentile), the fracture risk reduction was 38% (HR 0.62, 0.46–0.84).

Conclusions

The estimation of an individual’s 10-year probability of fracture by the FRAX® algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy.
Literature
1.
McCloskey E et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19(5):728–736PubMedCrossRef
2.
Delmas PD et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE Study. Osteoporos Int 15(10):792–798PubMedCrossRef
3.
Harris ST et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352PubMedCrossRef
4.
Black DM et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535–1541PubMedCrossRef
5.
Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082PubMedCrossRef
6.
Reginster J et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMedCrossRef
7.
McClung MR et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMedCrossRef
8.
Siris ES et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822PubMedCrossRef
9.
Wainwright SA et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90(5):2787–2793PubMedCrossRef
10.
Black DM et al (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12(7):519–528PubMedCrossRef
11.
Dargent-Molina P et al (1996) Fall-related factors and risk of hip fracture: the EPIDOS Prospective Study. Lancet 348(9021):145–149PubMedCrossRef
12.
Miller PD et al (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164(10):1113–1120PubMedCrossRef
13.
Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046PubMedCrossRef
14.
McCloskey EV et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22(1):135–141PubMedCrossRef
15.
Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRef
16.
Breslow NE, Day NE (1987) Statistical methods in cancer research, vol II. IARC Scientific Publications No 32, Lyon, pp 131–135
17.
(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843, pp 1–129
18.
Kanis JA et al (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7(4):390–406PubMedCrossRef
19.
Nelson HD et al (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(6):529–541PubMed
20.
Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326(7387):469PubMedCrossRef
21.
Rossouw JE et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 288(3):321–333PubMedCrossRef
22.
Kanis JA et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 33(3):293–300PubMedCrossRef
23.
Marcus R et al (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18(1):18–23PubMedCrossRef
24.
Watts NB et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88(2):542–549PubMedCrossRef
25.
Dargent-Molina P et al (2002) Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS Prospective Study. Osteoporos Int 13(7):593–599PubMedCrossRef
26.
Leslie WD et al (2002) Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. J Clin Densitom 5(2):117–130PubMedCrossRef
27.
McGrother CW et al (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) Study. Osteoporos Int 13(1):89–96PubMedCrossRef
28.
De Laet C et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16(11):1330–1338PubMedCrossRef
29.
Johnell O et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194PubMedCrossRef
30.
31.
Kanis JA et al (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 16:799–804PubMedCrossRef
32.
Kanis JA et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35(5):1029–1037PubMedCrossRef
33.
Kanis JA et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899PubMedCrossRef
34.
Kanis JA et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382PubMedCrossRef
35.
36.
Kanis JA; on behalf of the WSG (2007) Assessment of osteoporosis at a primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield
37.
Johansson H et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(6):906–913PubMedCrossRef
38.
Bauer DC et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292–299PubMedCrossRef
Metadata
Title
Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study
Authors
E. V. McCloskey
H. Johansson
A. Oden
S. Vasireddy
K. Kayan
K. Pande
T. Jalava
J. A. Kanis
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 5/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0786-9

Other articles of this Issue 5/2009

Osteoporosis International 5/2009 Go to the issue

Original Article

Sequential change in quality of life for patients with incident clinical fractures: a prospective study

Erratum

Features of the metabolic syndrome and the risk of non-vertebral fractures: The Tromsø Study

Erratum

Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø Study

Original Article

Secular trends in hip fracture incidence and recurrence

Original Article

Olympic fencers: adaptations in cortical and trabecular bone determined by quantitative computed tomography

Review

Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface